StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Stifel Comments On Valeant (VRX) Earnings
May 9, 2017 10:25 AM
Stifel maintains Buy on Valeant Pharmaceuticals (NYSE: VRX) price target of $45.00.Analyst Annabel Samimy stands out as one of two ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
May 9, 2017 7:05 AM